KASHIN HOTO:
Sunan bugu
Neman gaba
Outlook yana ganin sake ƙaddamar da aikace-aikacen FDA don maganin ido a ƙarshen 2024
Bayanin mahada
Shidlovski Outlook Therapeutics (NASDAQ: OTLK) ya ce yana tsammanin samun damar sake gabatar da aikace-aikacensa don amincewar FDA na maganinta na ONS-5010 don maganin jika mai alaƙa da macular degeneration a ƙarshen 2024, yana jiran yarjejeniya ta ƙarshe tare da FDA. bisa ƙa'idar ƙarin ...
- Turanci: Sunan buguNeman gaba
- Mai kula da hanyar haɗi: superadmin
- Nuwamba 27, 2023
Magana 263 
